For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Tafamidis meglumine represents a true change. These groundbreaking therapies stabilize the transthyretin protein, halting its damaging read more build-up and alleviating the burden of the illness. Individuals are now seeing